Stay updated with breaking news from Arcutis Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW ORLEANS — Izokibep, a novel interleukin-17 inhibitor, has shown dramatic responses in hidradenitis suppurativa treatment in an early phase 2 study, according to a speaker at the American Academy of Dermatology Annual Meeting.“[Hidradenitis suppurativa (HS)] is a horrible, horrible disease with a high disease burden. It’s extremely disruptive to anyone’s personal
Kazia Therapeutics (NASDAQ:KZIA – Get Rating) and Arcutis Biotherapeutics (NASDAQ:ARQT – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk. Profitability This table compares Kazia Therapeutics and Arcutis Biotherapeutics’ […]
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Rating) and Intellipharmaceutics International (OTCMKTS:IPCIF – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations. Valuation and Earnings This table compares Arcutis Biotherapeutics and […]